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Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and
organizing phase diffuse alveolar damage, especially in the elderly. The virus-host interactions that governed development
of these acute end stage lung diseases and death are unknown. To address this question, we evaluated the role of innate
immune signaling in protection from human (Urbani) and a recombinant mouse adapted SARS-CoV, designated rMA15. In
contrast to most models of viral pathogenesis, infection of type I, type II or type III interferon knockout mice (129
background) with either Urbani or MA15 viruses resulted in clinical disease outcomes, including transient weight loss,
denuding bronchiolitis and alveolar inflammation and recovery, identical to that seen in infection of wildtype mice. This
suggests that type I, II and III interferon signaling play minor roles in regulating SARS pathogenesis in mouse models. In
contrast, infection of STAT12/2 mice resulted in severe disease, high virus titer, extensive pulmonary lesions and 100%
mortality by day 9 and 30 post-infection with rMA15 or Urbani viruses, respectively. Non-lethal in BALB/c mice, Urbani SARS-
CoV infection in STAT12/2 mice caused disseminated infection involving the liver, spleen and other tissues after day 9.
These findings demonstrated that SARS-CoV pathogenesis is regulated by a STAT1 dependent but type I, II and III interferon
receptor independent, mechanism. In contrast to a well documented role in innate immunity, we propose that STAT1 also
protects mice via its role as an antagonist of unrestrained cell proliferation.
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Introduction
SARS Coronavirus (SARS-CoV) is a highly pathogenic
respiratory virus that emerged in China during the winter of
2002 and infected about 8,000 people globally and resulted in
,800 deaths, with greatly increased mortality rates in persons over
50 years of age (WHO). On initial isolation of SARS-CoV from
infected patients, it was identified as a novel Group 2 Coronavirus
and the genetic mechanisms governing the increased pathogenicity
of the virus remain undefined [1,2]. In severe cases, SARS-CoV
infection rapidly progressed to acute respiratory distress syndrome
(ARDS) during the acute phase of infection or to an organizing
phase diffuse alveolar damage following virus clearance; two
clinically devastating end stage lung diseases. The molecular
mechanisms governing these severe end stage lung disease
outcomes are unknown, although similar pathologies have been
reported following H5N1 and 1918 influenza virus infection.
The innate immune response is a key first line of defense against
invading pathogens and is dependent on various signaling
pathways and sensors that ultimately induce hundreds of anti-
viral proteins to establish a suboptimal environment for replication
and spread of invading pathogens [3,4]. During virus infection the
type I interferon (IFN) induction and signaling machinery is key to
the initiation of this response. IFN induced from either infected
cells or dendritic cells can activate an antiviral state in neighboring
cells to signal that a viral infection is under way[5]. Not
surprisingly, virus infections (mouse hepatitis virus, influenza virus,
RSV, alphaviruses, flaviviruses, etc.) of rodents that lack type I or
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and mortality, documenting the key role IFNs play in regulating
disease outcomes[6–12].
Given the importance of the IFN system in regulating virus
growth, many highly pathogenic viruses encode proteins that
antagonize components of the innate immune system. The Ebola
virus encodes VP35 which blocks STAT1 signaling[13,14],
influenza NS1 blocks IRF3 activation[15,16] and V proteins from
the Nipah and Hendra viruses induce STAT1 degradation[17].
Several IFN antagonist genes are encoded in the SARS-CoV
genome and target IFN sensing and signaling and NFKB
induction[18–21]. However, the role of IFN in regulating
SARS-CoV pathogenesis in vivo is less clear. From microarray
studies using RNA from PBMC’s for 50 SARS patients, Cameron
et. al. observed a robust type I IFN response early in the disease
and predicted that it was essential for viral clearance and clinical
recovery[22]. In addition to a strong IFN response, genes such as
CCL2 (MCP-1) and CXCL10 (IP-10) that are typically induced by
IFN were also up-regulated in patients at early times in SARS-
CoV disease. Interestingly, Cameron and colleagues suggested that
the IFN response that served to protect recovered SARS patients
could become a dysregulated cytokine storm in severe cases and
contribute to increased disease and a suboptimal adaptive immune
response. The innate immune response to SARS-CoV also
changes with age of the host; 12 month old BALB/c mice respond
to SARS-CoV with an exacerbated and faster innate immune
induction than 6 to 8 week old mice, potentially explaining their
increased susceptibility and lung pathology following infec-
tion[23,24].
Several studies have demonstrated the importance of the innate
response in viral clearance. Respiratory syncytial virus (RSV) and
SARS-CoV require MyD88 to produce an effective immune
response to control severe infection in the lung [25,26]. The Mx
gene product plays an important role in the susceptibility of
rodents to influenza virus infection and could regulate severity of
SARS-CoV disease in vivo as well[27]. Glass et al demonstrated that
SARS-CoV was cleared from the lungs of wildtype C57BL/6 mice
and strains that lacked that T, B and NK cells with similar kinetics,
suggesting that the innate immune response alone is sufficient for
viral clearance [28]. Hogan et. al. also demonstrated that STAT1,
a key modulator of IFN a/b, l, c signaling, was required for the
resolution of wildtype SARS-CoV infection, once again indicating
the importance of the innate response in the clearance of SARS-
CoV [29].
In this paper, we compare the pathogenesis of both the
epidemic virus (Urbani) and an isogenic, highly pathogenic mouse-
adapted SARS-CoV (rMA15) in different mouse strains, each
deficient in different innate immune signaling components.
Specifically, we tested the role of type I, type II, and type III
IFN and STAT1 in protection from SARS-CoV infection. We
have found that absence of the IFN a/b, IFNc and IFNl,
receptors alone or in some instances together, had a limited impact
on pathogenicity and clearance of the non-lethal and lethal strains
of SARS-CoV in mice. However, STAT1 deficient mice show
increased susceptibility, prolonged virus shedding and mortality
following infection with either virus. Importantly, STAT12/2
animals developed an organizing phase DAD, similar to lesions
noted in severe late stage human cases of SARS. Our data reveals
a new mechanistic pathway by which STAT1 regulates the
severity of viral pathogenesis in the lung. We show that SARS-
CoV pathogenesis is STAT1 dependent but independent of type I,
II and III IFN signaling, and we provide evidence consistent with
an essential role for STAT1 in the control of SARS-CoV
replication, cell proliferation, wound repair and progression to
severe organizing phase DAD and lethal disease.
Results
IFNa/b and IFNc receptor knockout mice and 129 WT
mice survive SARS-CoV infection
To understand the role of type I (IFNa/b) and type II IFN
(IFNc) in the response to SARS-CoV infection we infected IFN
receptor 2/2 mice with either a late phase SARS-CoV (Urbani)
virus or a recombinant isogenic mouse-adapted virus (rMA15) that
contained six virulence modifying mutations [30], anticipating that
the mouse-adapted virus may display more prominent pathoge-
nicity than the Urbani virus. The Urbani virus and the equivalent
recombinant icSARS viruses are not lethal in 10-wk old BALB/c,
C57BL6 and 129 WT mice, typically replicating in the lungs with
a peak titer at 2 days post-infection (dpi) before being cleared over
the next 2–4 days without clinical disease or mortality [26,30]. In
contrast, the rMA15 virus is lethal in 10-wk old BALB/c mice
causing greater than 20% weight loss by 4 days post-infection and
death by 4–5 days post-infection. We infected 129 WT, Type I
IFN receptor knockout mice (IFNAR12/2) and Type I/II double
IFN receptor knockout mice (IFNAGR2/2) with the Urbani
virus (Figure S1) and 129 WT, IFNAR12/2 and IFNGR2/2
with the rMA15 virus (Figure 1).
In 129 WT, IFNAR12/2 and IFNGR2/2 mice, clinical
findings including weight loss data and morbidity were identical
after infection with rMA15. 129 WT, IFNAR12/2 and
IFNGR2/2 mice infected with rMA15 virus lost ,15% of their
weight by day 4 and then steadily recovered over the next 5 days
(Figure 1). In contrast, Urbani virus infected mice continued to
gain weight through the course of infection (Figure S1). In both
cases, virus titers in the lungs peaked at day 2 post-infection,
approaching titers of ,5.0610
7 pfu or TCID50/g (rMA15 or
Urbani, respectively), and all were rapidly cleared by day 9 post-
infection. Although virus titers were ,5-fold higher in IFNAR12/
2 mice than titers in 129 WT mice on day 5 post-infection, we
found that IFNAR12/2 and IFNGR2/2 mice showed no
increase in susceptibility, pathogenesis or histological outcomes to
rMA15 or Urbani virus infection. To examine the importance of
cooperative IFN pathways in disease, IFN receptor double
knockout (IFNAGR2/2) mice were infected with the Urbani
virus; no increase in virus titer or weight loss was seen compared to
Author Summary
The SARS coronavirus is a highly pathogenic respiratory
virus that caused the first epidemic of the 21
st century.
During the epidemic ,10% of those infected died and the
elderly were particularly vulnerable. Severe cases devel-
oped acute lung injury with pulmonary fibrosis and Acute
Respiratory Distress Syndrome (ARDS). Little is known
about the molecular mechanisms governing its virus
pathogenesis and high lethality. Using a mouse model of
infection with the epidemic strain of SARS-CoV (Urbani) as
well as a recombinant mouse adapted strain of SARS-CoV
(rMA15), we showed that a protein normally associated
with the innate immune response, STAT1, plays an
important role in the development of severe end stage
lung injury. However, the lack of a normal innate immune
type I, type II and type III interferon response did not
enhance virus pathogenesis. Our work suggests that
STAT1 may play a key role in development of acute lung
injury and other chronic lung pathology, most likely by
affecting cell proliferation and wound repair pathways.
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S1). These data suggest that neither type I nor type II IFN
receptors are critical for the regulation of SARS-CoV infection
and pathogenic outcomes in mice.
STAT1 protects mice from rMA15 and Urbani virus
infection
In contrast to the results from IFN receptor knockout mice,
previous studies have suggested that STAT1 2/2 mice do not
clear the Urbani virus by day 22 post-infection[29]. We infected
STAT12/2 mice to evaluate whether the absence of a
downstream IFN signaling protein results in increased susceptibil-
ity to SARS-CoV infection, and to determine the course of
infection and pathologic changes associated with the virulent
mouse-adapted virus. Importantly, STAT12/2 mice infected
with rMA15 virus were more susceptible to disease than 129 WT,
IFNAR12/2 or IFNGR2/2 mice. Following rMA15 virus
infection, STAT12/2 mice lost 15% of their starting weight by
day 4 and continued to lose weight through day 9 post-infection
(Figure 1). As weight loss approached 30%, the mice were
moribund and succumbed to lethal infection. In stark contrast and
consonant with earlier reports, STAT12/2 mice infected with
Urbani virus initially gained weight as 129 WT mice did, through
day 12 post-infection (Figure S1). However, over the next 15 days
they displayed worsening clinical disease and lost significant body
weight. They did not recover by day 29 post-infection, and 30% of
them died.
Lung virus titers in STAT12/2 mice were also higher at each
timepoint tested compared to the titers seen in IFN receptor
knockout and 129 WT mice, (Figure 1B). When infected with
rMA15 virus, STAT12/2 mice showed higher peak virus titers in
the lungs at day 2 (,10
8 pfu/g) that remained as high as
.10
6 pfu/g at day 9 post-infection, while 129 WT mice had
cleared the virus by 9 days. Urbani virus infected STAT12/2
mice also showed increased and sustained virus replication in the
lungs as late as 15 days post-infection while virus was detectable
only through day 5 post-infection in the 129 WT mice (Figure
S1E). Taken together, these data suggest that a STAT1-
dependent, IFN type I and II receptor-independent pathway
plays a key role in regulating viral clearance and survival following
SARS-CoV infection.
Pulmonary disease associated with rMA15 virus infection
in 129 WT and IFN receptor and STAT1 knockout mice
Lungs from the various mouse strains infected with SARS-CoV
were analyzed for severity of histopathology (Figure 2). In the 129
WT mice, rMA15 virus caused a denuding bronchiolitis at 2 days
post-infection with significant apoptosis of airway epithelial cells
(noted by multilobed nuclei, condensed chromatin and nuclear
blebbing), accumulation of apoptotic debris within the airways and
perivascular cuffing caused predominately by lymphocytes. Similar
lesions have been noted in BALB/c and C57BL6 mice[26].
rMA15 virus infection was primarily localized in airway
epithelium at day 2 post-infection (Figure 3) and did not
disseminate to other areas of the lung or respiratory tract. Some
perivascular cuffing was noted in the vasculature by day 2 post-
infection as well. By day 5, the denuding bronchiolitis, obstruction
of the conducting airways by apoptotic debris and apoptosis of the
airway epithelium were rarely observed, although perivascular
cuffing and a mixed inflammatory response with lymphocytic
infiltration of eosinophils, neutrophils and macrophages was more
prominent. By day 9 post-infection, the remaining inflammation
caused by rMA15 virus infection was primarily found in
peribronchiolar areas (Figure 2).
Histologic changes in the lungs of IFNAR12/2 and
IFNGR2/2 mice were similar to 129 WT mice; the inflamma-
tion found in lung sections was temporally related to viral titer. At
day 2 post-infection, a denuding bronchiolitis characterized by
significant apoptosis and cell death in the airway epithelium was
observed and conducting airways were obstructed by apoptotic
debris. A mixed infiltrate composed of lymphocytes, neutrophils
and eosinophils was seen surrounding the bronchial epithelium. By
day 5 post-infection, significant inflammation was evident
throughout the lungs and alveoli, resulting in a mild to moderate
pneumonitis. As noted in lungs from 129 WT mice, the
inflammation was clearing by day 9 post-infection; minimal
Figure 1. Mouse adapted SARS-CoV (rMA15) infection of 129 WT, IFNAR12/2, IFNGR2/2 and STAT12/2 mice. A. 10 week old female
129 WT, IFNAR12/2, IFNGR2/2 and STAT12/2 mice were infected intranasally with 1610
5 pfu/ml rMA15 virus. Individual mice were weighed daily
and their average weight change from day 0 is presented. 10 mice per timepoint and strain were used in each group. The *= a p value of .001. B. At
days 2, 5 and 9 post-infection, groups of mice described in A were sacrificed and lungs were dissected, homogenized and supernatant used to titer
virus in a plaque assay on Vero cells. Plotted is the average pfu/g of lung for 5 mice per group for each timepoint. The # = a p value of .005 and the
* = a p value of .001. Each is a comparison of Day 9 WT compared to Day 9 STAT12/2.
doi:10.1371/journal.ppat.1000849.g001
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minor peribronchial lymphocytes remained.
At day 2 post-infection with rMA15 virus, lung lesions in
STAT12/2 mice were indistinguishable from those seen in 129
WT, IFNAR12/2 and IFNGR2/2 infected animals. By day 5
post-infection, lung lesions were more severe in STAT12/2
mice, consistent with persistently high virus titers (Figure 2). Two
features were notable; first, the extent of inflammation was more
severe in STAT12/2 mice, with a much greater number of
macrophages infiltrating into all areas of the lung, a finding that
Figure 2. Histopathology of rMA15 virus infected mouse strains. Mice were sacrificed at days 2, 5 and 9 post-infection for histopathological
analysis. Lung sections were stained with H&E and photomicrographs of individual airways are shown in the figure. The left side of each matched pair
is a 10X picture and the right side is 40X.
doi:10.1371/journal.ppat.1000849.g002
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alveolar septa was seen throughout the lungs with perivascular and
peribronchial thickening. By 9 days post-infection, the inflamma-
tion continued to increase in STAT12/2 mice while lung
inflammation was subsiding in 129 WT, IFNAR12/2 and
IFNGR2/2 infected mice. In STAT12/2 mice, inflammation
was pervasive throughout the lungs with densely packed
infiltrating cells especially prominent throughout the periphery
Figure 3. In situ hybridization of rMA15 infected mouse lungs. A. Paraffin embedded mouse lungs where sectioned and probed with S
35
labeled probe complementary to SARS-CoV nucleocapsid RNA. Representative samples from days 2, 5 and 9 post-infection (dpi) are shown. Not
shown are slides probed with a non-specific probe, which showed no labeling at all. Mock infected samples also showed no labeling. B. High
magnification image of a 9 day post-infection STAT12/2 mouse lung with a corresponding H&E stained slide next to it. Note that areas with in situ
signal overlap with areas of infiltration in the H&E stained section.
doi:10.1371/journal.ppat.1000849.g003
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residing in the alveolar interstitium. Interestingly, large foci
containing densely packed fibroblasts, macrophages and lympho-
cytes were seen throughout the lungs and scattered atypical large
cells were found throughout the foci. A focal mixed inflammatory
infiltrate was found with extensive fibrin deposition. Pleuritis
signified by a breakdown of the pleura was seen in most samples as
well. This pathology was consistent with proliferative and
organizing phase diffuse alveolar damage (DAD). It is noteworthy
that similar pathologic lesions were seen in many fatal SARS cases
[31–34].
Pulmonary disease associated with SARS-CoV Urbani
virus infection in mice
Lesions developing from days 2 to 9 in 129 WT, IFNAR12/2
and IFNAGR2/2 mice inoculated with the Urbani virus were
similar to those seen in rMA15-infected 129 WT mice. At days 2–
3, there was diffuse bronchial and bronchiolar necrosis and
migration of leukocytes (CD3+ T-cells, neutrophils and eosino-
phils) through vessel walls to peribronchiolar and perivascular
areas but extension of lesions into the alveoli was not prominent
(Figure S1F). Viral antigen was seen within the bronchial and
bronchiolar epithelium (data not shown) as previously pub-
lished[35]. By day 5, less necrosis was seen in the bronchiolar
epithelium but peribronchiolar and perivascular cuffing remained.
At day 9, necrosis was not observed and only minor perivascular
cuffing was present. At days 15 and 22–29, the lungs were mostly
normal except for minor perivascular and peribronchiolar cuffing
of lymphocytes.
In STAT12/2 mice infected with the Urbani virus, there was
a similar distribution of bronchial and bronchiolar lesions in the
lung as seen in the 129 WT mice at day 3, but with more necrosis
and inflammation. Edema was observed around peribronchiolar
blood vessels and the larger inflammatory cell infiltrate contained
many lymphocytes, and neutrophils with a few eosinophils and
macrophages. Abundant viral antigen was seen in bronchiolar
epithelium (data not shown). By day 5, the bronchiolar epithelium
had foci of regeneration with little necrosis and the peribronchiolar
and perivascular inflammation was less severe than at day 3. Plugs
of cellular debris and fibrin filled some bronchioles. A blue tinge
was noted in the perivascular edema fluid, suggesting early
collagen deposition. Viral antigen was much less common in the
epithelium but was abundant in the cellular debris in the airways.
At day 9, inflammatory cells increased around residual inflam-
matory lesions, with abundant neutrophils and more macrophages
in the lesions. Marked epithelial hyperplasia was also seen in these
foci. Bronchiolitis obliterans was seen in a few airways and
interstitial lesions developed around some airway lesions, one of
which extended to the pleura and producing focal pleuritis. Much
of the lung parenchyma was, however, histologically normal. Only
a few cells or cell debris was seen expressing viral antigen. By day
15, a fibrinous pleuritis with pyogranulomatous lesions developed
in 2 of 3 mice, with focal resolving parenchymal lesions including a
few foci of chronic interstitial pneumonia but most of the lung
parenchyma remained fairly normal. From day 15–24, a fibrinous
peritonitis (Figure S2A), pleuritis and pyogranulomatous lesions in
spleen, liver and omentum developed as the major lesions that
likely contributed to illness and death in the STAT12/2 mice
(Figure S2B-F). These lesions were characterized by a central area
of necrosis with numerous neutrophils and an outer zone of
macrophages. Viral antigen was found in some of the macro-
phages in these pyogranulomatous lesions (Figure S2D, E). Plasma
cells became abundant in the splenic lesions by day 24 (Figure
S2G). Abundant fibrosis (detected by Masson’s trichrome stain)
was seen in the splenic and liver lesions at day 24 (Figure S2F).
The lungs of mice from days 15–24 were mostly normal with areas
of residual chronic inflammation and a few pyogranulomas, some
of which contained viral antigen. The pleura had nodules of
pyogranulomatous and fibrinous inflammation.
In situ hybridization of rMA15 virus infected lungs
We determined the localization of virus in infected lungs during
the course of infection by in situ hybridization. We used a
riboprobe complementary to the SARS-CoV nucleocapsid RNA
that was labeled with radioactive nucleotides to visualize viral
RNA in the tissue. In situ hybridization was performed on lungs
from 129 WT, IFNAR12/2, IFNGR2/2 and STAT12/2
mice harvested at days 2, 5, and 9 post-infection. In all 4 strains of
mice, the probe signal was predominantly localized in the airway
epithelial cells at day 2 post-infection (Figure 3A). This correlated
with the pathologic lesions in airway epithelial cells at day 2 post-
infection. By day 5 post-infection, viral RNA was virtually
eliminated from the control 129, and IFNAR12/2 mice and to
a slightly lesser extent in IFNGR2/2 mice. Occasionally, a few
cells with viral RNA were noted in the periphery, consistent with
the low titers of virus in these animals at day 5. By day 9, there was
no viral RNA signal found in the lungs of 129 WT, IFNAR12/2
and IFNGR2/2 mice, corresponding to the lack of viral
replication at this time point. In contrast, lungs of STAT12/2
mice showed significant viral RNA signal throughout the lungs,
including prominent distribution into the periphery of the lung at
early and late times post-infection. Surprisingly, but consistent
with the findings on histopathology, viral RNA signal was lost
from the airway epithelial cells in the bronchioles by day 9 in
STAT12/2 mice and was found throughout the periphery of the
lungs, prominently focused in large focal compactions of cells.
These foci correspond to the prominent focal lesions noted in
H&E stained sections of the lung, which are predominantly
composed of fibroblasts, macrophages and lymphocytes
(Figure 3B). Interestingly, cellular debris can be seen in these foci
that may represent lysed airway epithelial cells.
Characterization of inflammatory cell infiltrates
We observed marked differences in pathology of lungs from 129
WT mice compared to STAT12/2 mice after infection with the
rMA15 virus. To investigate whether STAT1 affected the
inflammatory infiltrate, we isolated leukocytes from enzymatically
disrupted mouse lungs harvested on day 8 post-infection and used
cell surface markers to quantify macrophage (CD11c
2/CD11b
+/
GR-1
int/MHCII
+), neutrophil (F480
2/CD11b
+/CD11c
2/GR-
1
+), and eosinophil (CD11c
2/Siglec
+/GR-1
2) populations in
129 WT and STAT12/2 mice. A greater than 10-fold difference
in leukocyte numbers was found between 129 WT and STAT12/
2 infected mice (Table 1). As shown in Table 1, the eosinophil
population increased from ,2% in 129 WT mice to ,30% in
STAT12/2 mice and neutrophils increased from 3% in 129 WT
mice to 35% in STAT12/2 mice. Additionally, the number of
macrophages in STAT12/2 mice was more than double that
detected in 129 WT mice. These numbers are concordant with the
histological findings by H&E staining at 9 days post-infection.
Cytokine and chemokine protein and gene expression
studies
We used real time RT-PCR and CBA analysis to quantify
changes in mRNA and protein expression levels of several innate
immune factors involved in pulmonary inflammation. Specifically,
we compared the induction of several pro-inflammatory cytokines
SARS-CoV Pathogenesis
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infection by analyzing lung homogenates by CBA (Figure 4A, B, C
and D) or quantitative RT-PCR to measure levels of mRNAs in
Urbani virus or rMA15 virus infected mice, respectively (Figure 4E,
F, G and H).
In Urbani virus infected lungs, minimal changes were seen in
129 WT, IFNAR12/2, IFNAGR2/2 mice for all 4 cytokines
(Figure 4A, B, C and D). However, in STAT1 2/2 mice,
significant increases in protein expression patterns were detected
across different time points, peaking between 9 and 15 days post-
infection. TNFa protein levels increased steadily from day 2
through day 29 post-infection while IL6 and IFNc protein levels
peaked at day 9, before reducing to levels seen in mock infected
animals. MCP1 protein levels were increased between days 5
through 22 but diminished by day 29 post-infection.
Cytokine induction following rMA15 virus infection was
compared with Urbani virus infection (Figure 4A–H). Comparing
cytokine transcript levels on days 2, 5 and 9 post-infection, we
noted some similarities and important differences. Following
rMA15 virus infection, 129 WT mice showed a 10-fold induction
of TNFa transcripts by day 2 post-infection, followed by
progressively reduced levels of expression that returned to baseline
by day 9. While IFNAR12/2 mice showed similar kinetics as 129
WT mice, infection in IFNGR2/2 mice resulted in a continued
rise in TNFa expression till day 9. In contrast, STAT12/2 mice
had low baseline levels of TNFa expression through day 5, after
which high levels of expression were noted at day 9, corresponding
to the peak time of inflammation in the lungs, just prior to death.
IFNc and MCP1 gene expression levels were similar in rMA15
virus-infected 129 WT, IFNAR12/2 and IFNGR-/mice.
Transcript levels were induced by day 2 and then decreased
through day 9. While STAT12/2 infected mice showed a similar
trend of increased transcript levels at day 2, expression levels of
IFNc and MCP1 continued to increase through day 9 post-
infection. Finally, IL6 expression showed similar kinetics in
rMA15 virus infected 129 WT control and IFNAR12/2 mice
with peaks at day 2 that decreased to baseline levels by day 5.
IFNGR2/2 mice showed similar kinetics, but with lower
expression levels at day 2. Comparatively, induction of IL6 in
STAT12/2 mice followed a different pattern, with high levels of
expression at day 2 post-infection and persistent high level
expression through day 9. IFNb, IFNa4, IL28B, IL18, IRF1
and OAS1 were analyzed by Real-time PCR from lung RNA
isolated during the rMA15 timecourse in WT, IFNAR2/2 and
STAT12/2 mice (Figure S3). IFNb, IFNa4, IL28B, IRF1 and
OAS1 show a peek of induction at 2dpi for all 3 strains with a
reduction throughout the timecouse with a few exceptions. IFNb,
IFNa4 and OAS1 show either a sustained or late burst in
expression of each in only the STAT12/2 mice. Interestingly,
IL18 shows minimal induction (,1.5 fold) in WT mice but even
less in the IFNAR2/2 and STAT12/2 mice. Thus, significant
differences in cytokine expression patterns were noted between
STAT1, WT and IFNAR deficient animals, where typically WT
and IFNAR2/2 mice had the same expression patters while
STAT12/2 mice were typified by perceived loss of regulatory
control and persistent high level expression.
Type III IFN does not play a role in SARS-CoV
pathogenesis
STAT1 is a mediator of Type III IFN (IFN L, Lambda)
signaling in addition to Type I and II IFN signaling. IFNL is
minimally but significantly upregulated during infection in WT
129 mice at day 2 post infection which decreases through the
course of 9 days post infection (Figure 5A). The receptor for IFNL
is a heterodimer of IL10Rb and IL28Ra. IL28Ra2/2 mice have
been generated on the BALB/c mouse background but not on the
129 WT mouse background. Thus, although direct comparison
with the other mouse strains is not possible, experiments with
SARS-CoV in these mice are still informative. As in the C57B6
background, the Urbani virus does not cause disease or weight loss
but the virus replicates in the lungs of BALB/c mice. Virus reaches
peak titer by day 2 post-infection and infection is resolved by day
7[36]. In contrast, rMA15 virus infection of BALB/c mice causes
death by day 4 or 5 post-infection[30]. We hypothesized that if
IFNL was important for protection from SARS-CoV infection, the
virus would be more virulent in mice lacking the IFNL receptor
and IFNL receptor knockout mice would show evidence of disease
while normal BALB/c mice would not. Further, rMA15 virus
infection of IL28Ra2/2 mice may result in enhanced pathology
with more weight loss, higher virus titer, or increased lung
pathology.
This hypothesis was tested by inoculating control BALB/c mice
and IL28Ra2/2 mice with the Urbani virus, rMA15 virus or
PBS. There was no weight loss in either BALB/c or IL28Ra2/2
mice infected with the Urbani virus (data not shown), thus the lack
of IFNl signaling did not potentiate clinical disease. Lungs from
Urbani virus infected BALB/c and IL28Ra2/2 mice were
harvested at 2, 4, 7 and 21 days post-infection. We found no
difference between the titers of virus in the lungs of BALB/c and
IL28Ra2/2 mice (Figure 5B). Lungs from infected mice were
analyzed by H&E staining. Urbani virus infection of IL28Ra2/2
mice produced mild inflammation that peaked at day 2 and
Table 1. Quantitation of the inflammatory cell infiltrate in the lungs of rMA15 virus infected STAT12/2 mice at 8dpi.
Percent (number) of cells in the lungs of indicated strains of mice following mock or rMA15 infection
129 + PBS STAT12/2 + PBS 129 + rMA15 STAT12/2 + rMA15
Total leukocytes isolated 12,702 14,823 13,211 160,561
Dendritic Cells 1.8% (236) 2.3% (110) 12.97% (1,713) 16.8% (26,902)
Macrophages 1.2% (154) 1.1% (53) 8.6% (1,137) 13.4% (21,490)
Neutrophils 2.6% (377) 3.3% (159) 2.2% (293) 30.8% (49,411)
Eosinophils 1.2% (150) 0.7% (337) 0.8% (107) 16.3% (26,119)
Analysis of inflammatory cell infiltrates during rMA15 infection of STAT12/2 mice. Lymphocytes from lungs of 129 WT and STAT12/2 mice infected with rMA15 or PBS
for 8 days, were isolated and labeled with antibodies to identify inflammatory cell populations by flow cytometry. Macrophages were identified as CD11c
2/CD11b
+/GR-
1
int/MHCII
+ cells, neutrophils as F480
2/CD11b
+/CD11c
2/GR-1
+ cells and eosinophils as CD11c
2/Siglec
+/GR-1
2 cells. The percent of total starting lymphocytes is shown
in the table for each cell type.
doi:10.1371/journal.ppat.1000849.t001
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BALB/c mice (Figure S4A).
rMA15 virus infection caused .20% weight loss and/or death
by day 4-5 post-infection in BALB/c and similar findings in
IL28Ra2/2 mice (data not shown); both lost ,20% weight by
day 4 post-infection. Lungs were harvested at days 2 and 4 post-
infection and no differences in virus titers were observed
(Figure 5B). Both mouse strains showed peak virus titers at day
2 with a 2-3 log decrease by day 4. Lung pathology was analyzed
by H&E staining. Both BALB/c and IL28Ra2/2 mice showed
similar high levels of inflammation at 2 and 4 days post-infection,
but remarkably similar pathologic outcomes (Figure S4B). Taken
together, we found no role for IFNl in protection from infection
with either the Urbani or rMA15 strains of SARS-CoV.
IFNLR antibody in IFNAR12/2 mice
BALB/c and 129 WT mice respond differently to rMA15 virus
infection; rMA15 is lethal in BALB/c mice but only causes
transient weight loss in 129/Sv mice. To analyze the effects of
knocking out both Types I and III IFN signaling pathways, we
treated IFNAR12/2 mice (on the 129 background) with
neutralizing antibodies to IL28Ra, the receptor used by IFNl.
Figure 4. Protein and gene expression analysis of cytokines. A–D. A cytometric bead array was used to quantify the protein levels of
cytokines in lung homogenates after infection with the Urbani virus. Lung samples were homogenized and protein levels of (A) TNFa, (B) IFNc, (C)
MCP1 and (D) IL6 were quantified. E–F. Real-time PCR analysis was performed on RNA from infected mouse lungs. Mice were harvested at days 2, 5
and 9 post-infection and lung RNA isolated by Trizol. cDNA was made from 1ug of RNA of each and used in real-time analysis and the results for 3
mice per group were combined. Fold increase over mock-infected lungs of each cytokine is graphed for (E) TNFa, (F) IFNc, (G) MCP1 and (H) IL6.
doi:10.1371/journal.ppat.1000849.g004
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1, 1, 3, 5 and 7 days post-infection as described in the
literature[37]. We found no difference in weight loss or
pathogenesis of rMA15 in these mice compared to mice injected
with PBS (Figure 6). Mice showed 15% weight loss by day 4 post-
infection but recovered by day 9, ending at their starting weight.
Lungs were analyzed at days 2, 4 and 9 post-infection and showed
no difference in pathology compared to IFNAR12/2 mice (data
not shown). Both groups of mice showed epithelial cell denudation
at 2 day post-infection and repair and clearance by day 9. Virus
titers were only slightly increased over PBS injected mice but the
difference was not statistically significant. This suggests that the
inhibition of both Type I and Type III signaling in mice does not
increase the pathogenesis of the rMA15 virus and neither protect
129 mice from disease.
Discussion
Paradigm of IFN signaling and protection
SARS-CoV infection in humans rapidly progressed from an
atypical pneumonia, to acute phase diffuse alveolar damage and
ARDS during the first 10 days of acute lung injury. In many
patients this is followed by the development of an organizing phase
DAD after virus clearance. Both pathologies were associated with
severe clinical outcomes and death, especially prominent in the
elderly. The molecular mechanisms and virus-host signaling
networks that regulate these progressive end stage lung diseases
are unknown but are of considerable importance, given the global
disease burden associated with them. Previous studies in our
laboratory have demonstrated that aged mice infected with
recombinant viruses encoding S glycoproteins from early phase
Figure 5. Pathogenesis of Urbani and rMA15 viruses in IL28Ra2/2 mice. BALB/c and IL28Ra2/2 mice were infected with 1610
5 pfu of
either Urbani or rMA15 virus. A. Real time analysis of IL28B transcripts was performed on WT 129 infected mice at 2, 5 and 9 days post infection.
Graphed is the fold increase over 18S RNA for each mouse with 5 mice at each timepoint averaged together. B. Titer of Urbani and rMA15 virus at
each timepoint. Lungs were homogenized and supernatant of each lung was titered by plaque assay on Vero cells. Shown is the average titer from 5
mice at each timepoint. The level of detection is shown by a dotted line at 100 pfu/ml.
doi:10.1371/journal.ppat.1000849.g005
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by hyaline membranes and DAD. In this report, we show that
STAT1 deficient mice are especially prone to the development of
organizing phase DAD.
The innate immune system plays a centralrole in regulating early
host responses to virus infection and promoting adaptive immune
responses. The Type I, II and III IFNs are typically produced by
different cell populations and use distinct membrane bound
receptors to gain entry into cells; Type I uses IFNAR1, Type II
uses IFNGR and Type III uses IL28Ra/IL10Rb. However, all
three sharea commoncytoplasmicsignalingprotein,called STAT1,
that is translocated to the nucleus and induces expression of
multiple, overlapping IFN regulated genes (ISGs)[38]. Deletion of
any or all of the signaling components involved in the STAT1
signaling pathway diminishes the innate immune response to
pathogens and increases susceptibility to several bacterial and viral
agents. Mice lacking IFN receptors show increased susceptibility to
West Nile[9], influenza[12,39], Ebola[11], Friend virus[40],
RSV[7,8] and Poliovirus[41] (reviewed in [42]). Moreover, the
same phenotypes are noted in STAT1 2/2 mice, demonstrating a
key role of the entire innate immune pathway in regulating disease
severity, viral titers, and pathology[10]. In stark contrast, we
demonstrate the paradoxical finding that SARS-CoV Urbani and
rMA15 viruses induce severe end stage lung disease by a STAT1
dependent mechanism that is independent of IFN receptor typeI, II
and III signaling. The data point to a novel mechanism by which
STAT1 function regulates disease severity in the lung following
SARS-CoV induced acute lung injury.
New paradigms for STAT1 regulation of acute lung injury
In contrast to the existing paradigm, SARS-CoV infection is
successfully controlled and cleared in IFNAR12/2, IFNGR2/2,
Figure 6. IFNL receptor antibody treatment of IFNAR12/2 mice. IFNAR12/2 mice were treated with 100mg of anti-IL28Ra antibody and
infected with rMA15 virus. A. Mock infected (PBS) and antibody injected IFNAR12/2 mice were infected with 1610
5 pfu/ml rMA15 virus at day 0.
Average weights for each group are plotted compared to starting weights (5 mice per group). B. Mouse lungs were harvested at days 2, 4 and 9 post-
infection. Virus titer in lung homogenates were determined on Vero cells. 5 mice were used per timepoint and the average titer of the group of 5
mice is shown.
doi:10.1371/journal.ppat.1000849.g006
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leads to increased virus replication, morbidity and mortality
following infection with either the human epidemic strain of
SARS-CoV (Urbani) or a mouse adapted strain (rMA15). These
results suggest a novel mechanism of STAT1 regulation of severe
end stage lung disease following SARS-CoV infection that is
independent of it’s roles in IFN signaling and ISG expression.
Although it is possible that cooperative combinations of several
IFNs (IFNa/b, IFNc, IFNl) that signal through STAT1 are
required to regulate SARS-CoV infection, we feel that the
possibility exists that STAT1’s role in controlling cell proliferation
and wound healing may be the base cause of the increased disease
seen in STAT12/2 mice. Nevertheless, the development of triple
knockouts affecting all 3 IFN receptors would address this
mechanistic possibility.
Alternative roles for STAT1
STAT1 functions a key gatekeeper in mediating IFNa/b, IFNc
and IFNl signaling into the nucleus to induce overlapping but
distinct ISGs. Less well appreciated in viral pathogenesis studies,
STAT1 also plays key roles in cell cycle arrest and cell
proliferation[43–45]. Thus, STAT1 defects may augment viral
lung disease by several potential mechanisms. STAT1 was shown
to be an important controller of tumor formation in several types
of cancers including lung, colon, pancreatic and brain cancers[46–
48] and its role in cell proliferation has been studied in the context
of pulmonary fibrosis[43]. STAT12/2 mouse fibroblasts showed
increased proliferation when exposed to growth factors compared
to WT mouse fibroblasts. Additionally, STAT12/2 mice
demonstrated a greater susceptibility to chemically induced
pulmonary fibrosis via bleomycin treatment. These data suggested
that outside of the innate immune response, STAT1 may function
as a key regulator of cell proliferation and of the wound healing
response[49]. Our data also suggest that STAT1 may regulate the
wound healing response following acute lung injury associated
with viral infection, similar to its cell cycle regulation seen in other
models of disease.
STAT1 and SARS-CoV
Lungs of STAT12/2 mice infected with rMA15 virus
progressed to an early stage pulmonary fibrosis-like disease in 9
days. The acute lung injury (ALI) seen in these lungs approximates
the damage seen in ARDS that was often seen in severe cases of
SARS in humans[50], especially in the elderly. We found
perivascular cuffing, collapse of alveolar parenchyma, invasion
and amplification of macrophages, neutrophils, eosinophils and
fibroblasts and most importantly, extensive fibrin deposition
throughout the lungs. These pathological findings mirror those
seen in ALI, pulmonary fibrosis and ARDS.
SARS-CoV, like many highly pathogenic viruses, expresses
several proteins that antagonize the IFN sensing and amplification
network. SARS-CoV ORF6 blocks STAT1 nuclear import[18],
PLP blocks IRF3 activation[51], NSP7[51], NSP15[51], ORF3b
and N have been shown to be IFN antagonists as well[19].
Importantly, these antagonists only function in the context of
SARS-CoV infection within discrete permissive cells. This suggests
that in infected cells, the multiple pathways that inhibit IFN
signaling may create essentially a STAT2/2 environment which
may contribute to the further pathology seen during disease. As
has been described with influenza, it is likely that a cytokine storm
significantly contributes to increased pathogenic outcomes by
targeting non-infected cells. The loss of STAT1 in other cells of
the knockout mouse may contribute as we have described here, to
loss of wound healing control and induction of fibrosis, leading to
the development of the lethal disease state after SARS-CoV
infection.
The molecular mechanisms governing SARS-CoV pathogenesis
have only recently begun to be evaluated using mice with targeted
genetic defects challenged with the rMA15 virus. Sheahan et. al.
identified a role for Myd88, an adapter protein of TLR signaling,
and RAG1, necessary for antibody production, in protection from
infection and disease. Myd88 2/2 mice showed an enhanced
susceptibility to rMA15 virus infection in C57/B6 mice[26] and
RAG12/2 mice showed no increased morbidity and mortality
from rMA15 virus infection, viral replication in the lungs was
detectable through 28 days post-infection[26]. These data suggest
that an intricate balance between the innate and adaptive immune
response is necessary for protection from SARS-CoV infection.
We are currently working on understanding how these two
processes interact in the host. Using proteomic and microarray
analyses Cameron et al[22] showed that individuals who survived
SARS-CoV infection had controlled innate immune, ISG and
cytokine responses while individuals who progressed to severe
disease demonstrated an uncontrolled innate immune response,
with high levels of ISG and immunoglobulin expression, increased
cytokine responses and poor antibody responses to the spike
protein. The cause of this lack of regulation is not understood.
Comparison of Urbani to rMA15 virus
Infection with the epidemic (Urbani) and mouse adapted strains
of SARS-CoV caused increased pathology in the STAT12/2
mice. Thus, it seems likely that the mouse adapted mutations in
rMA15 enhanced the intrinsic pathogenic properties of SARS-
CoV to produce severe end stage lung disease in the mice.
However, SARS-CoV Urbani spreads from the respiratory tract
into the spleen and liver of STAT12/2 mice. This suggests that
although the damage may have been induced by viral infection,
the pathology results from the host’s response to the infection,
though it is not clear whether this represents a normal pattern of
spread or whether mutations have evolved in the virus that
promote spread and distribution to other organs. Similar findings
were seen in autopsy samples from individuals who died from
SARS. Airways were intact and regenerated while acute cases
showed spread to the outer pulmonary parenchyma[52].
The similarities between STAT12/2 mice infected with
SARS-CoV and elderly individuals infected with SARS-CoV
during the epidemic are intriguing. Recent work has shown that in
cells from aged hosts, STAT1 signaling cascades are less
responsive to stimuli; STAT1 signaling in aged macrophages were
hypo-responsive to IFNc[49]. As observed in our study, IFNc
expression increases substantially in STAT12/2 mice. We
hypothesize that this may be in response to a lack of negative
feedback via the STAT1 signaling pathway. During the SARS
epidemic, aged individuals were the cohort with most severe
disease and highest mortality rates[53]. We propose that altered
STAT1 signaling in aged individuals may have lead to increased
susceptibility to severe disease.
We cannot rule out the possibility that all 3 types of IFN
receptors are redundant for SARS-CoV mediated disease and that
only by deleting all 3 types of receptors will be observe an increase
in pathogenesis. Proof must await the availability of a mouse strain
containing the deletion of all three receptors. However we find
that the type of pathology produced in STAT12/2 mice by both
WT and rMA15 SARS-CoV demonstrates a role for STAT1 in
non-innate immune processes that resemble those produced in
severely infected SARS-CoV patients.
We propose a new potential pathway by which STAT1
regulates end stage lung disease following viral infection. We
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results from different roles of STAT1 in the cell. First, loss of
STAT1 results in a deficient IFN response that results in higher
titers of virus in the lungs. Secondly, loss of STAT1 allows for
unregulated cell proliferation in response to the innate immune
response, causing enhanced damage to the lungs and death of the
animals. Our findings also point to an increasing role of the cell
damage response to viral infection that can be potential targets for
therapy in highly pathogenic respiratory infections.
Methods
Ethics statement
All mice in this study were treated following IACUC guidelines.
For infection mice were pre-treated with Ketamine and Xylazine
as an anesthetic. Mice were euthanized if their weight dropped
below 20% of their starting weight or if clinical symptoms
warranted it per our IACUC approvals. Animal housing and care
and experimental protocols were in accordance with all UNC-
Chapel Hill Institutional Animal Care and Use Committee
guidelines or NIH guidelines, depending where the experiments
were performed.
Viruses and cells
Vero E6 cells were grown in MEM (Invitrogen, Carlsbad, CA)
supplemented with 10% FCII (Hyclone, South Logan, UT) and
gentamicin/kanamycin (Gibco-BRL). Stocks of the biological
SARS-CoV (Urbani), recombinant SARS-CoV (icSARS) and
mouse-adapted SARS-CoV (rMA15) were propagated and titered
on Vero or Vero E6 cells and cryopreserved at 280uC until use as
described [30]. All experiments with infectious virus were
performed in a Class II biological safety cabinet in a certified
biosafety level 3 laboratory containing redundant exhaust fans
with personnel wearing protective equipment including Tyvek
suits, hoods, and HEPA-filtered powered air-purifying respirators
(PAPRs) as described [30].
Mice
129S6/SvEv wildtype and STAT12/2 mice (catalog number
002045-M-F) were obtained from Taconic Farms (Germantown,
NY). For the mouse adapted SARS-CoV infections, Type I IFN
receptor deficient (IFN alpha/beta receptor) (IFNAR12/2) mice
were bred in at the UNC mouse facility (Chapel Hill, North
Carolina). Type II IFN receptor deficient (IFN gamma receptor)
(IFNGR2/2) mice (stock number 002702) were purchased from
The Jackson Laboratories (Bar Harbor, ME). For the Urbani virus
infections, IFNAR12/2 mice were obtained as a gift from Dr.
Joan Durbin at Ohio State University and IFN alpha/beta/
gamma receptor double knockout (IFNAGR2/2) mice were bred
at the NIH animal facility (Bethesda, MD). IFN-lambda receptor
knockout mice (IL28Ra2/2, Zymogen, Seattle, Washington)
were bred at the UNC Chapel Hill animal facility. Animal housing
and care and experimental protocols were in accordance with all
UNC-Chapel Hill Institutional Animal Care and Use Committee
guidelines or NIH guidelines, depending where the experiments
were performed. All animal studies were conducted in Animal
Biosafety Level 3 laboratories using SealSafe Hepa-filtered caging
and personnel wore personal protective equipment, including
Tyvek suits and hoods and positive pressure HEPA-filtered air
respirators. 10 week old mice were anesthetized with a mixture of
ketamine/xylazine or isoflurane and intranasally infected with
either PBS alone or 10
5 pfu/50 ml rMA15 or the recombinant or
biological epidemic virus, icSARS or Urbani, in PBS (Invitrogen,
Carlsbad, CA). Mice were monitored at 24 h intervals for virus-
induced morbidity and mortality. Subsets of mice were euthanized
at days 2, 5, and 9 post-infection (dpi) for characterization of
rMA15 infection, while the less pathogenic Urbani virus infected
animals were sampled on days 2, 3, 5, 9, 15, 22 and 29 post-
infection. All tissues were analyzed for histopathology changes and
for viral titers.
Viral replication in organs
To quantify the amount of infectious virus in tissues from
rMA15 infection, each organ was weighed, placed in 0.5 ml
DPBS, homogenized, and titered via plaque assay on Vero E6 cells
as previously described [26]. For Urbani infection, supernatants of
10% (w/v) lung homogenates were prepared and titrated on Vero
cell monolayers in 24- and 96-well plates as previously described
[40]. Virus titers are expressed as TCID50 per g of tissue. The
lower limit of detection was 10
1.5 TCID50/g.
Histological analysis
Lung tissues were fixed in PBS/4% para-formaldehyde, pH 7.3,
embedded in paraffin, and 5 mm sections were prepared by the
UNC histopathology core facility. To determine the extent of
inflammation, sections were stained with hematoxylin and eosin
(H & E) and scored in a blinded manner.
BD Cytometric Bead Array (CBA) for protein expression
Supernatants of 20% (weight/volume) lung homogenates were
used for detection of cytokines and chemokines using BD CBA kits
(BD Biosciences) according to the manufacturer’s instructions. The
lower limit of detection for each protein is included in the kit
protocol.
In situ hybridization
35S-UTP-labeled riboprobes specific to the N gene of SARS-
CoV (Urbani) or to the EBER2 gene from Epstein-Barr virus
(negative control probe) were generated with an SP6-specific
MAXIscript in vitro transcription kit (Ambion) and in situ
hybridization was performed as described previously[26]. Briefly,
deparaffinized tissue sections were hybridized with 5610
4 cpm/ml
of
35S-labeled riboprobes overnight. Tissues were washed,
dehydrated through graded ethanol, coated in NTB autoradiog-
raphy emulsion (Kodak), and incubated at 280uC for 7 days.
Following development, sections were counterstained with hema-
toxylin and silver grain deposition was analyzed by light
microscopy. rMA15-specific signal was determined by comparing
silver grain deposition on parallel sections hybridized with the
35S-
labeled riboprobe complementary for the EBER2 gene of Epstein-
Barr virus.
Real-time PCR analysis
Lungs from mock or SARS-CoV infected mice were removed
and homogenized directly in 1 ml of Trizol reagent (Invitrogen)
and total RNA was isolated following manufacturer’s instructions.
Complementary cDNA was generated from 1 mg of total RNA
using 250 ng random primers (Invitrogen) and Superscript II
reverse transcriptase (Invitrogen). Real-time PCR experiments
were performed using Taqman gene expression assays and an ABI
Prism 7300 (Applied Biosystems). 18S rRNA was used as an
endogenous control to use for normalization in all assays. The
relative fold induction of amplified mRNA were detected using the
Ct method. Taqman primer sets used were 18S (#Hs03003631
Applied Biosystems), IFNc (Mm00801778 Applied Biosystems),
TNFa (Mm99999068 Applied Biosystems), MCP1 (Mm99999056
Applied Biosystems), IFNB (Mm00439552 Applied Biosystems),
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Applied Biosystems), IL18 (Mm00434225 Applied Biosystems),
IRF1 (Mm01288574 Applied Biosystems) and OAS1
(Mm00449297).
Flow cytometry
Mice were inoculated as described above, sacrificed by
exsanguination at 2 and 4 days post-infection, and lungs were
perfused via cardiac puncture with 16PBS. Lungs were dissected,
minced, and incubated for 2 hrs with vigorous shaking at 37uCi n
digestion buffer [RPMI, 10% FBS, 15 mM HEPES, 2.5 mg/ml
collagenase A (Roche), 1.7 mg/ml DNase I (Sigma)]. Cells were
passed through a 40 micron cell strainer, resuspended in RPMI
media, layered on 5 ml lympholyte-M (Cedarlane), and centri-
fuged 30 min at 2500 rpm. Cells were collected, washed in wash
buffer (16 HBSS, 15 mM HEPES), and total viable cells were
determined by trypan blue exclusion. Isolated cells were incubated
with anti-mouse FccRII/III (2.4G2; BD Pharmingen) for 20 min
on ice and then stained in FACS staining buffer (16HBSS, 1%
FBS, 2% normal rabbit serum) with the following antibodies from
eBioscience: anti-F4/80-FITC, anti-Gr-1-PE, anti-CD11b-APC,
anti-CD11c-PE, anti-Ly-6C-FITC, anti-CD3-FITC, anti-CD8-
APC, anti-CD4-PerCP, and anti-NK1.1-PE. Cells were fixed
overnight in 2% paraformaldehyde and analyzed on a Cyan
cytometer (Dako) using Summit software.
Statistical analyses
Percent starting weights, viral titers and inflammatory cell
numbers were evaluated for statistically significant differences by
the non-parametric Mann-Whitney test within GraphPad Prism or
unpaired t-tests using GraphPad InStat3 software. P values of
#0.05 were considered significant.
Supporting Information
Figure S1 Urbani virus infection of 129 WT (A), IFNAR12/2
(B), IFNAGR2/2 (C) and STAT12/2 (D) mice. Mice were
infected with the Urbani virus and weighed each day for 29 days.
Shown is their average weight change from day 0 across each
group (n.5). E. Mice were harvested at each timepoint and lung
homogenates determined in Vero cells are expressed as mean
TCID50 per gram of lung for each group. F. Urbani virus infected
mouse lungs stained with H&E. A representative lung from each
mouse strain across the timecourse is shown. Note the increased
inflammation in the lungs of STAT12/2 mice through the
course of disease, especially at day 15 post-infection.
Found at: doi:10.1371/journal.ppat.1000849.s001 (6.33 MB TIF)
Figure S2 Gross pathology of lungs and peripheral organs of
Urbani virus infected mice. A. Gross lesions in organs from an
Urbani virus infected STAT12/2 mouse 15 dpi showing a
fibrinous exudate on the spleen and nodules on the liver. B. Lung
from a STAT12/2 mouse 24 dpi displaying a pyogranulomatous
nodule. H&E, X100. C. Spleen from a STAT12/2 mouse 24 dpi
showing the central area of the pyogranuloma with neutrophils on
left and macrophages on the right side. H&E, X400. D. Liver of a
STAT12/2 mouse stained with anti-SARS-CoV antibody
showing viral antigen in macrophages on edges of pyogranuloma.
Hematoxylin, IHC, X400. E. Spleen of STAT12/2 mouse 24
dpi, showing many pyogranulomas. H&E, X40. F. Spleen of
STAT12/2 mouse at 24 dpi stained with Mason’s Trichome
stain, showing collagen (blue) in zones around the pyogranulomas,
X100. G Spleen of STAT12/2 mouse infected with Urbani virus
22 dpi stained with anti-kappa light chain, showing numerous
plasma cells adjacent to the pyogranuloma. Hematoxylin, IHC,
X200.
Found at: doi:10.1371/journal.ppat.1000849.s002 (7.14 MB TIF)
Figure S3 Real Time analysis on innate immune response
genes. RNA from rMA15 infected WT, IFNAR2/2 and
STAT12/2 mice was extracted and used for Realtime analysis
of (A) IFNB, (B) IFNA, (C) IL18B, (D) IL18, (E) and (F) OAS1.
Graphed is the fold increase over 18S rRNA for each sample at 2,
5 and 9 days post infection. For each timepoint, RNA from 5 mice
was harvested and the average is shown with the standard
deviation of each sample set.
Found at: doi:10.1371/journal.ppat.1000849.s003 (0.48 MB EPS)
Figure S4 A. Lungs from mice infected with Urbani virus were
harvested at days 2, 4, 7 and 21 post-infection (n=5 for each
timepoint). Shown are representative sections from IL28Ra2/2
mouse lungs stained with H&E at each timepoint. B. Mice were
infected with rMA15 virus and lungs were harvested at days 2 and
4 post-infection. The infection was lethal for both BALB/c and
IL28Ra2/2 mice by day 4 post-infection. Uninfected BALB/c
mouse lungs are shown as a comparison.
Found at: doi:10.1371/journal.ppat.1000849.s004 (4.65 MB TIF)
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